Physician profile
Boris Furman
NPI 1164695011
$12,002.37
in general payments reported to CMS, 2019-2025
59 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 92% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $881 · 2021: $1,992 · 2022: $2,119 · 2023: $1,839 · 2024: $1,757 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,453 · Education: $26.73 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.21 |
| Education | $26.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,116.27 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $1,045.19 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,006.29 | 2019-2025 | |
| Abbvie INC. | $999.52 | 2021-2025 | |
| Lilly USA, LLC | $783.33 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $600.56 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $598.66 | 2019-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $541.56 | 2019-2025 | Nourianz |
| Ucb, INC. | $468.58 | 2019-2025 | Rystiggo |
| Pfizer INC. | $444.06 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $257.13 | 2020-2025 | Spravato |
| Sk Life Science, INC. | $255.98 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $249.07 | 2019-2021 | |
| Grifols USA, LLC | $235.90 | 2019-2025 | Gamunex-C |
| Lundbeck LLC | $235.18 | 2022-2025 | Rexulti, Vyepti |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.